🇺🇸 FDA
Pipeline program

TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB

IJB-ZEPHIR02-2024

Phase 2 small_molecule active

Quick answer

TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB for advanced/metastatic HER2-positive breast carcinoma is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
advanced/metastatic HER2-positive breast carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials